We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: GS1-10) was presented at the virtual SABCS 2020, 8-11 December 2020.
- Could you tell us a little about radioactive iodine seed localisation and the history of its use to date in breast cancer therapy?
- What was the rationale for combining radioactive iodine seed localisation in the axilla with the sentinel node procedure (RISAS) for cancer staging after neoadjuvant chemotherapy?
- Could you give us an overview of the RISAS study and its findings?
- What are the implications of these findings for clinical practice?
- How do you expect the use of radioactive seed localisation to develop in the future?
Speaker Disclosures: Dr Janine Simons has nothing to disclose in relation to this video interview. Dr Janine Simons was previously at the Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands, where the RISAS study was conducted.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the San Antonio Breast Cancer Symposium (SABCS) 2020.
Share this Video
Related Videos In Breast Cancer
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!